DRUGS MADE IN AMERICA ACQUIS (DMAA) Stock Price, Forecast & Analysis
NASDAQ:DMAA • KYG2847J1040
DMAA Key Statistics, Chart & Performance
The current stock price of DMAA is 10.46 USD. In the past month the price increased by 0.48%. In the past year, price increased by 4.91%.
DMAA Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to DMAA. When comparing the yearly performance of all stocks, DMAA turns out to be only a medium performer in the overall market: it outperformed 48.67% of all stocks.
DMAA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to DMAA. The financial health of DMAA is average, but there are quite some concerns on its profitability.
DMAA Financial Highlights
Over the last trailing twelve months DMAA reported a non-GAAP Earnings per Share(EPS) of 0.2.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | 2.29% | ||
| ROE | 2.37% | ||
| Debt/Equity | 0 |
DMAA Forecast & Estimates
DMAA Ownership
About DMAA
Company Profile
Drugs Made In America Acquisition Corp. is a blank check company, which engages in the provision of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses. The company is headquartered in Fort Lauderdale, Florida. The company went IPO on 2025-01-28. The firm is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses. The firm intends to focus its search for businesses in the pharmaceutical industry. The firm has neither engaged in any operations nor generated any revenues.
Company Info
DRUGS MADE IN AMERICA ACQUIS
1 East Broward Boulevard, Suite 700
Fort Lauderdale FLORIDA US
Employees: 0
Phone: 19548703099
DRUGS MADE IN AMERICA ACQUIS / DMAA FAQ
What does DMAA do?
Drugs Made In America Acquisition Corp. is a blank check company, which engages in the provision of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses. The company is headquartered in Fort Lauderdale, Florida. The company went IPO on 2025-01-28. The firm is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses. The firm intends to focus its search for businesses in the pharmaceutical industry. The firm has neither engaged in any operations nor generated any revenues.
Can you provide the latest stock price for DRUGS MADE IN AMERICA ACQUIS?
The current stock price of DMAA is 10.46 USD.
Does DRUGS MADE IN AMERICA ACQUIS pay dividends?
DMAA does not pay a dividend.
What is the ChartMill technical and fundamental rating of DMAA stock?
DMAA has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the Price/Earnings (PE) ratio of DRUGS MADE IN AMERICA ACQUIS (DMAA)?
The PE ratio for DRUGS MADE IN AMERICA ACQUIS (DMAA) is 52.3. This is based on the reported non-GAAP earnings per share of 0.2 and the current share price of 10.46 USD.
What is the ownership structure of DRUGS MADE IN AMERICA ACQUIS (DMAA)?
You can find the ownership structure of DRUGS MADE IN AMERICA ACQUIS (DMAA) on the Ownership tab.